Multivalent Vaccines Market Report 2025

This Multivalent Vaccines market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The multivalent vaccines market size has grown strongly in recent years. It will grow from $8.37 billion in 2024 to $9.2 billion in 2025 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to rising public awareness for vaccination, increasing government support, increasing demand for pediatric multivalent vaccines, increasing funding for vaccine research, and rising demand for multivalent vaccines.

The multivalent vaccines market size is expected to see strong growth in the next few years. It will grow to $13.32 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to the rising incidence of infectious illnesses, increasing numbers of geriatric population, increasing government and private sector investment, growing focus on vaccine safety and effectiveness, and growing focus on therapeutic vaccines. Major trends in the forecast period include greater emphasis on combination vaccines, integration of digital health technologies, development in mRNA technology, development of personalized vaccines, and increase in research activities.

The increasing prevalence of infectious diseases is projected to significantly drive the growth of the multivalent vaccines market in the near future. Infectious diseases are caused by pathogens such as bacteria, viruses, fungi, or parasites, which can be transmitted through direct contact or contaminated surfaces, air, or water, varying in severity from mild to severe. The global travel landscape facilitates the rapid spread of these diseases, allowing pathogens to easily cross borders and infect new populations. Multivalent vaccines offer broader protection against infectious diseases by targeting multiple pathogen strains in a single dose, reducing the necessity for multiple shots. This comprehensive coverage enhances herd immunity and decreases disease prevalence, thereby improving public health outcomes. For example, a report released by TravelHealthPro in April 2024 noted that the UK reported 2,004 malaria cases in 2023, an increase from the 1,369 imported cases in 2022. As a result, the rising incidences of infectious diseases are a key factor driving the growth of the multivalent vaccines market.

Leading companies in the multivalent vaccines sector are concentrating on the development of advanced pentavalent vaccines to enhance overall public health outcomes by providing wider protection in a single dose. A pentavalent vaccine is specifically designed to safeguard against five distinct pathogens or strains. This consolidation of protections simplifies immunization schedules and improves overall vaccine coverage. For instance, in December 2023, Panacea Biotec Ltd., an India-based biotechnology firm, introduced EasyFourPol, the world’s first fully liquid vaccine. This innovative vaccine protects against five serious diseases, including diphtheria, tetanus, pertussis, polio, and invasive infections from Haemophilus influenzae Type B. By eliminating the need for preparation by healthcare professionals, this ready-to-use combination vaccine streamlines the vaccination process. It offers equivalent protection to single-antigen vaccines, reduces the number of clinic visits required for children, and lowers overall immunization costs. Moreover, it enhances vaccination efficiency and minimizes environmental impact by decreasing the requirement for vials, syringes, and packaging.

In February 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Icosavax Inc. for $1.1 billion. This acquisition allows AstraZeneca to strengthen its late-stage pipeline with IVX-A12, enhancing its presence in the RSV vaccine market. The deal also incorporates Icosavax's expertise in protein design and virus-like particles (VLP), providing a foundation for developing additional multivalent vaccines targeting respiratory viruses. Icosavax Inc. is a US-based biotechnology company specializing in the creation of multivalent vaccines utilizing a protein virus-like particle (VLP) platform.

Major companies operating in the multivalent vaccines market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Moderna Inc., BioNTech SE, Zydus Lifesciences Limited, CSL Seqirus, Sinovac Biotech Ltd., GC Biopharma corp., Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Indian Immunologicals Ltd., Bavarian Nordic, Panacea Biotec Ltd., WestVac Biopharma Co. Ltd., VBI Vaccines Inc.

North America was the largest region in the multivalent vaccines market in 2023. The regions covered in the multivalent vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the multivalent vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Multivalent vaccines are strategically formulated to provide protection against multiple strains or types of a single pathogen, or against several distinct pathogens, within a single administration. By incorporating antigens from various strains or diseases, these vaccines facilitate the development of immunity against multiple targets simultaneously, thereby delivering broader protection than monovalent vaccines, which focus exclusively on a single strain or pathogen.

The primary categories of multivalent vaccines include conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, toxoid vaccines, and recombinant vaccines. Conjugate vaccines enhance immune recognition and efficacy by linking a weaker antigen to a stronger one, which is particularly beneficial for combating bacterial diseases. These vaccines are applicable for a range of diseases, including influenza, pneumonia, hepatitis, meningitis, and rotavirus, and can be administered via various routes, such as oral and injectable methods. They are designed for a diverse demographic, encompassing pediatric, adult, and geriatric populations, and are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The multivalent vaccines market research report is one of a series of new reports that provides multivalent vaccines market statistics, including multivalent vaccines industry global market size, regional shares, competitors with a multivalent vaccines market share, detailed multivalent vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the multivalent vaccines industry. These multivalent vaccines market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The multivalent vaccines market consists of sales of bivalent vaccines, trivalent vaccines, and polyvalent vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.